Abstract
Though deletion of the long arm of chromosome 6 is one of the most common aberrations in tumors, its targeted gene(s) has not been convincingly identified. Using a functional screening approach, we found that UTRN (which encodes utrophin, a dystrophin-related protein) at 6q24, when expressed in an antisense orientation, induced cellular transformation, consistent with a tumor suppressor role. Northern blot analysis, semiquantitative reverse transcription–polymerase chain reaction (RT–PCR), and gene expression arrays all showed that UTRN expression was downregulated in primary tumors compared with matched normal tissues. Several UTRN neighbor genes were not affected in some tumors with UTRN downregulation, suggesting that UTRN was specifically targeted. RT–PCR, coupled with an in vitro transcription and translation assay, revealed inactivation mutations in 21/62 breast cancers, 4/20 neuroblastomas and 4/15 malignant melanomas. Most of the mutations were deletions involving one or more exons that led to the truncation of utrophin. Splicing errors were found in two cases, and nonsense mutation in one case. Overexpression of a wild-type UTRN in breast cancer cells inhibited tumor cell growth in vitro and reduced their tumor potential in nude mice. Our studies suggest that UTRN is a candidate tumor suppressor gene.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abe T, Makino N, Furukawa T, Ouyang H, Kimura M, Yatsuoka T et al. (1999). Identification of three commonly deleted regions on chromosome arm 6q in human pancreatic cancer. Genes Chromosomes Cancer 25: 60–64.
Acevedo CM, Henriquez M, Emmert-Buck MR, Chuaqui RF . (2002). Loss of heterozygosity on chromosome arms 3p and 6q in microdissected adenocarcinomas of the uterine cervix and adenocarcinoma in situ. Cancer 94: 793–802.
Atkin NB, Jackson Z . (1996). Clonal chromosome changes including a del(6q) in a possible early lymphoma. Cancer Genet Cytogenet 92: 87–89.
Barghorn A, Speel EJ, Farspour B, Saremaslani P, Schmid S, Perren A et al. (2001). Putative tumor suppressor loci at 6q22 and 6q23–q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am J Pathol 158: 1903–1911.
Biroccio A, Leonetti C, Zupi G . (2003). The future of antisense therapy: combination with anticancer treatments. Oncogene 22: 6579–6588.
Blake DJ, Schofield JN, Zuellig RA, Gorecki DC, Phelps SR, Barnard EA et al. (1995). G-utrophin, the autosomal homologue of dystrophin Dp116, is expressed in sensory ganglia and brain. Proc Natl Acad Sci USA 92: 3697–3701.
Brault E, Gautreau A, Lamarine M, Callebaut I, Thomas G, Goutebroze L . (2001). Normal membrane localization and actin association of the NF2 tumor suppressor protein are dependent on folding of its N-terminal domain. J Cell Sci 114: 1901–1912.
Chappell SA, Walsh T, Walker RA, Shaw JA . (1997). Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas. Br J Cancer 75: 1324–1329.
Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L et al. (1997). Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90: 717–727.
Fujioka Y, Taira T, Maeda Y, Tanaka S, Nishihara H, Iguchi-Ariga SM et al. (2001). MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia/lymphoma and tongue cancer. J Biol Chem 276: 45137–45144.
Gutmann DH, Sherman L, Seftor L, Haipek C, Hoang LK, Hendrix M . (1999). Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesionand spreading. Hum Mol Genet 8: 267–275.
Hoffman PJ, Milliken DB, Gregg LC, Davis RR, Gregg JP . (2004). Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis. Fertil Steril 82: 639–649.
Hu J, Schuster AE, Fritsch MK, Schneider DT, Lauer S, Perlman EJ . (2001). Deletion mapping of 6q21-26 and frequency of 1p36 deletion in childhood endodermal sinus tumors by microsatellite analysis. Oncogene 20: 8042–8044.
Huang LW, Garrett AP, Muto MG, Colitti CV, Bell DA, Welch WR et al. (2000). Identification of a novel 9 cM deletion unit on chromosome 6q23–24 in papillary serous carcinoma of the peritoneum. Hum Pathol 31: 367–373.
Jensen RH, Tiirikainen M, You L, Ginzinger D, He B, Uematsu K et al. (2003). Genomic alterations in human mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q. Anticancer Res 23: 2281–2289.
Li L, Cohen SN . (1996). Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 85: 319–329.
Mertens F, Johansson B, Hoglund M, Mitelman F . (1997). Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res 57: 2765–2780.
Morris GE, Sedgwick SG, Ellis JM, Pereboev A, Chamberlain JS, Nguyen TM . (1998). An epitope structure for the C-terminal domain of dystrophin and utrophin. Biochemistry 37: 11117–11127.
Moser H . (1984). Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention. Hum Genet 66: 17–40.
Negrini M, Sabbioni S, Possati L, Rattan S, Corallini A, Barbanti-Brodano G et al. (1994). Suppression of tumorigenicity of breast cancer cells by microcell-mediated chromosome transfer: studies on chromosomes 6 and 11. Cancer Res 54: 1331–1336.
Noviello C, Courjal F, Theillet C . (1996). Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletion. Clin Cancer Res 2: 1601–1606.
Offit K, Louie DC, Parsa NZ, Filippa D, Gangi M, Siebert R et al. (1994). Clinical and morphologic features of B-cell small lymphocytic lymphoma with del(6)(q21q23). Blood 83: 2611–2618.
Offit K, Parsa NZ, Gaidano G, Filippa DA, Louie D, Pan D et al. (1993). 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood 82: 2157–2162.
Pearce M, Blake DJ, Tinsley JM, Byth BC, Campbell L, Monaco AP et al. (1993). The utrophin and dystrophin genes share similarities in genomic structure. Hum Mol Genet 2: 1765–1772.
Pozzoli U, Sironi M, Cagliani R, Comi GP, Bardoni A, Bresolin N . (2002). Comparative analysis of the human dystrophin and utrophin gene structures. Genetics 160: 793–798.
Qu XY, Hauptschein RS, Rzhetsky A, Scotto L, Chien MC, Ye X et al. (1998). Analysis of a 69-kb contiguous genomic sequence at a putative tumor suppressor gene locus on human chromosome 6q27. DNA Seq 9: 189–204.
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: 1–6.
Roque L, Rodrigues R, Pinto A, Moura-Nunes V, Soares J . (2003). Chromosome imbalances in thyroid follicular neoplasms: a comparison between follicular adenomas and carcinomas. Genes Chromosomes Cancer 36: 292–302.
Schofield J, Houzelstein D, Davies K, Buckingham M, Edwards YH . (1993). Expression of the dystrophin-related protein (utrophin) gene during mouse embryogenesis. Dev Dyn 198: 254–264.
Theile M, Seitz S, Arnold W, Jandrig B, Frege R, Schlag PM et al. (1996). A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer. Oncogene 13: 677–685.
Tibiletti MG, Bernasconi B, Furlan D, Bressan P, Cerutti R, Facco C et al. (2001). Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms. Clin Cancer Res 7: 3404–3409.
Tibiletti MG, Bernasconi B, Furlan D, Riva C, Trubia M, Buraggi G et al. (1996). Early involvement of 6q in surface epithelial ovarian tumors. Cancer Res 56: 4493–4498.
Tibiletti MG, Sessa F, Bernasconi B, Cerutti R, Broggi B, Furlan D et al. (2000). A large 6q deletion is a common cytogenetic alteration in fibroadenomas, pre-malignant lesions, and carcinomas of the breast. Clin Cancer Res 6: 1422–1431.
Trent JM, Stanbridge EJ, McBride HL, Meese EU, Casey G, Araujo DE et al. (1990). Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science 247: 568–571.
Wan M, Sun T, Vyas R, Zheng J, Granada E, Dubeau L . (1999). Suppression of tumorigenicity in human ovarian cancer cell lines is controlled by a 2 cM fragment in chromosomal region 6q24–q25. Oncogene 18: 1545–1551.
Welch DR, Chen P, Miele ME, McGary CT, Bower JM, Stanbridge EJ et al. (1994). Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. Oncogene 9: 255–262.
Yamada H, Wake N, Fujimoto S, Barrett JC, Oshimura M . (1990). Multiple chromosomes carrying tumor suppressor activity for a uterine endometrial carcinoma cell line identified by microcell-mediated chromosome transfer. Oncogene 5: 1141–1147.
Acknowledgements
This research was supported by the US Department of Defense Breast Cancer Research Program (to SX). We are grateful to Dr Glenn E Morris at North East Wales Institute for providing the anti-utrophin antibody.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Li, Y., Huang, J., Zhao, YL. et al. UTRN on chromosome 6q24 is mutated in multiple tumors. Oncogene 26, 6220–6228 (2007). https://doi.org/10.1038/sj.onc.1210432
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210432
Keywords
This article is cited by
-
UTRN inhibits melanoma growth by suppressing p38 and JNK/c-Jun signaling pathways
Cancer Cell International (2021)
-
The Duchenne muscular dystrophy gene and cancer
Cellular Oncology (2021)
-
Dystrophin is a tumor suppressor in human cancers with myogenic programs
Nature Genetics (2014)
-
β2-syntrophin and Par-3 promote an apicobasal Rac activity gradient at cell–cell junctions by differentially regulating Tiam1 activity
Nature Cell Biology (2012)